NCT00577642View on ClinicalTrials.gov

Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Multiple Myeloma
Interventions
DRUG

Zoledronic acid

4mg IV over at least 15 minutes or corrected for creatinine clearance x 1

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

American Society of Clinical Oncology

OTHER

lead

Massachusetts General Hospital

OTHER

NCT00577642 - Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates | Biotech Hunter | Biotech Hunter